Vitae

Home > Vitae

Andy Yeh Alpha

Virtual net portfolio value:$9,837,567

Net overall return per annum:27.13%

Laura Hermes

Virtual net portfolio value:$5,445,980

Net overall return per annum:19.48%

Dan Rochefort

Virtual net portfolio value:$5,438,767

Net overall return per annum:19.46%

Charlene Vos

Virtual net portfolio value:$5,439,908

Net overall return per annum:19.46%

Jonah Whanau

Virtual net portfolio value:$5,417,271

Net overall return per annum:19.41%

Chanel Holden

Virtual net portfolio value:$5,390,430

Net overall return per annum:19.35%

Becky Berkman

Virtual net portfolio value:$5,382,763

Net overall return per annum:19.33%

Peter Prince

Virtual net portfolio value:$5,356,655

Net overall return per annum:19.27%

Jacob Miramar

Virtual net portfolio value:$5,345,509

Net overall return per annum:19.24%

Monica McNeil

Virtual net portfolio value:$5,331,848

Net overall return per annum:19.21%

Fiona Sydney

Virtual net portfolio value:$5,319,347

Net overall return per annum:19.18%

Daisy Harvey

Virtual net portfolio value:$5,284,734

Net overall return per annum:19.10%

Rose Prince

Virtual net portfolio value:$5,243,145

Net overall return per annum:19.00%

James Campbell

Virtual net portfolio value:$5,158,153

Net overall return per annum:18.80%

John Fourier

Virtual net portfolio value:$5,149,040

Net overall return per annum:18.78%

Olivia London

Virtual net portfolio value:$5,137,370

Net overall return per annum:18.75%

Apple Boston

Virtual net portfolio value:$5,073,236

Net overall return per annum:18.59%

Joseph Corr

Virtual net portfolio value:$4,938,839

Net overall return per annum:18.26%

Blog+More

President Trump ramps up 25% tariffs on $200 billion Chinese imports soon after China backtracks on the Sino-U.S. trade agreement.

Rose Prince

2019-05-09 10:28:00 Thursday ET

President Trump ramps up 25% tariffs on $200 billion Chinese imports soon after China backtracks on the Sino-U.S. trade agreement.

President Trump ramps up 25% tariffs on $200 billion Chinese imports soon after China backtracks on the Sino-American trade agreement. U.S. trade envoy Robe

+See More

Our proprietary alpha investment model outperforms most stock market indices from 2017 to 2023.

Daisy Harvey

2023-02-03 08:27:00 Friday ET

Our proprietary alpha investment model outperforms most stock market indices from 2017 to 2023.

Our proprietary alpha investment model outperforms most stock market indices from 2017 to 2023. Our proprietary alpha investment model outperforms the ma

+See More

Fed Chair Janet Yellen confirms with her successor Jerome Powell the final interest rate hike in December 2017.

Joseph Corr

2017-12-14 12:41:00 Thursday ET

Fed Chair Janet Yellen confirms with her successor Jerome Powell the final interest rate hike in December 2017.

Federal Reserve raises the interest rate by 25 basis points to the target range of 1.25% to 1.5% as FOMC members revise up their GDP estimate from 2% to 2.5

+See More

Barry Eichengreen compares the Great Depression of the 1930s and the Great Recession as historical episodes of economic woes.

Olivia London

2023-03-21 11:28:00 Tuesday ET

Barry Eichengreen compares the Great Depression of the 1930s and the Great Recession as historical episodes of economic woes.

Barry Eichengreen compares the Great Depression of the 1930s and the Great Recession as historical episodes of economic woes. Barry Eichengreen (2016)

+See More

Corporate strategies, portfolio choices, and management memes add value and drive business process improvements over time.

Jacob Miramar

2020-08-19 10:32:00 Wednesday ET

Corporate strategies, portfolio choices, and management memes add value and drive business process improvements over time.

Corporate strategies, portfolio choices, and management memes add value and drive business process improvements over time. Andrew Campbell, Jo Whitehead,

+See More

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle

John Fourier

2024-05-05 10:31:00 Sunday ET

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle In terms of stock market valuation, the major pharmaceutical sector remains at its

+See More